Supernus Pharmaceuticals, Inc. (SUPN) Profit Margins
Over the twelve months to 2026-06-30, Supernus Pharmaceuticals, Inc. (SUPN) had gross margin 88.1%, operating margin -15.7%, net margin -13.2%, free cash flow margin 2.3%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SUPNSupernus Pharmaceuticals, Inc.Follow SUPN — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 90.8% | 93.8% | 94.3% | 94.4% | 95.0% | 96.2% | 95.8% | — | 87.1% | 86.9% | 86.2% | 88.2% | 89.6% | 88.1% | |
| Operating margin | -2849.3% | -515.2% | -5.7% | 14.1% | 25.2% | 32.9% | 35.3% | 37.8% | 33.4% | 14.8% | 6.9% | -0.9% | 12.3% | -8.7% | -15.7% | |
| Net margin | -3127.3% | -767.7% | -11.8% | 9.5% | 42.4% | 19.0% | 27.1% | 28.8% | 24.4% | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% | -13.2% | |
| FCF margin | -3240.0% | -495.8% | -27.1% | 22.0% | 30.3% | 37.3% | 31.3% | 35.7% | 25.9% | — | 17.4% | 18.2% | 25.9% | 6.4% | 2.3% |
USD billions · SEC XBRL
Supernus Pharmaceuticals, Inc. — questions
- What is Supernus Pharmaceuticals, Inc.'s gross margin?
- 88.1% over the twelve months to 2026-06-30.
- What is Supernus Pharmaceuticals, Inc.'s operating margin?
- -15.7% over the twelve months to 2026-06-30.
- What is Supernus Pharmaceuticals, Inc.'s net profit margin?
- -13.2% over the twelve months to 2026-06-30.
Every figure on this page comes from Supernus Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.